Containing pandemic influenza with antiviral agents.

For the first wave of pandemic influenza or a bioterrorist influenza attack, antiviral agents would be one of the few options to contain the epidemic in the United States until adequate supplies of vaccine were available. The authors use stochastic epidemic simulations to investigate the effectiveness of targeted antiviral prophylaxis to contain influenza. In this strategy, close contacts of suspected index influenza cases take antiviral agents prophylactically. The authors compare targeted antiviral prophylaxis with vaccination strategies. They model an influenza pandemic or bioterrorist attack for an agent similar to influenza A virus (H2N2) that caused the Asian influenza pandemic of 1957-1958. In the absence of intervention, the model predicts an influenza illness attack rate of 33% of the population (95% confidence interval (CI): 30, 37) and an influenza death rate of 0.58 deaths/1,000 persons (95% Cl: 0.4, 0.8). With the use of targeted antiviral prophylaxis, if 80% of the exposed persons maintained prophylaxis for up to 8 weeks, the epidemic would be contained, and the model predicts a reduction to an illness attack rate of 2% (95% Cl: 0.2, 16) and a death rate of 0.04 deaths/1,000 persons (95% CI: 0.0003, 0.25). Such antiviral prophylaxis is nearly as effective as vaccinating 80% of the population. Vaccinating 80% of the children aged less than 19 years is almost as effective as vaccinating 80% of the population. Targeted antiviral prophylaxis has potential as an effective measure for containing influenza until adequate quantities of vaccine are available.

[1]  J. Oxford,et al.  Study of 1-adamantanamine hydrochloride used prophylactically during the Hong Kong influenza epidemic in the family environment. , 1969, Bulletin of the World Health Organization.

[3]  E. D. Kilbourne,et al.  The Influenza viruses and influenza , 1975 .

[4]  W. Gerhard,et al.  THE FUTURE IN VIRAL IMMUNOLOGY AND IMMUNOPATHOLOGY , 1975 .

[5]  A. Langworthy,et al.  An influenza simulation model for immunization studies. , 1976, American journal of epidemiology.

[6]  I. Longini,et al.  An optimization model for influenza A epidemics , 1978 .

[7]  R. Couch,et al.  Interpandemic influenza in the Houston area, 1974-76. , 1978, The New England journal of medicine.

[8]  A. Monto,et al.  Prevention of Russian influenza by amantadine. , 1979, JAMA.

[9]  N. Grist Pandemic influenza 1918. , 1979, British medical journal.

[10]  L. A. Rvachev,et al.  A mathematical model for the global spread of influenza , 1985 .

[11]  I. Longini,et al.  Tecumseh study of illness. XIII. Influenza infection and disease, 1976-1981. , 1985, American journal of epidemiology.

[12]  I. Longini The generalized discrete-time epidemic model with immunity: a synthesis , 1986 .

[13]  I M Longini,et al.  Predicting the global spread of new infectious agents. , 1986, American journal of epidemiology.

[14]  E Ackerman,et al.  Latin hypercube sampling and the sensitivity analysis of a Monte Carlo epidemic model. , 1988, International journal of bio-medical computing.

[15]  I M Longini,et al.  Statistical inference for infectious diseases. Risk-specific household and community transmission parameters. , 1988, American journal of epidemiology.

[16]  O. Diekmann,et al.  On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations , 1990, Journal of mathematical biology.

[17]  I. Longini,et al.  A generalized stochastic model for the analysis of infectious disease final size data. , 1991, Biometrics.

[18]  A S Perelson,et al.  Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. , 1998, The Journal of infectious diseases.

[19]  F. Hayden,et al.  The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. , 1998, The New England journal of medicine.

[20]  M. Meltzer,et al.  The economic impact of pandemic influenza in the United States: priorities for intervention. , 1999, Emerging infectious diseases.

[21]  M. Halloran,et al.  Design and interpretation of vaccine field studies. , 1999, Epidemiologic reviews.

[22]  A. Monto,et al.  Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. , 1999, JAMA.

[23]  A. Monto,et al.  Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. , 2000, The New England journal of medicine.

[24]  Lihan K. Yan,et al.  Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. , 2000, The Journal of pediatrics.

[25]  M E Halloran,et al.  Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. , 2000, Vaccine.

[26]  Tom Britton Epidemics in heterogeneous communities: estimation of "R" , 2001 .

[27]  E. Garman,et al.  The Origin and Control of Pandemic Influenza , 2001, Science.

[28]  F. Hayden,et al.  Perspectives on antiviral use during pandemic influenza. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[29]  J. Oxford,et al.  Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. , 2001, JAMA.

[30]  A. Nizam,et al.  Containing Bioterrorist Smallpox , 2002, Science.

[31]  A. Nizam,et al.  Community interventions and the epidemic prevention potential. , 2002, Vaccine.

[32]  Weber Antimicrobial Therapy and Vaccines , 2002 .

[33]  R. Webster,et al.  Are We Ready for Pandemic Influenza? , 2003, Science.

[34]  Keiji Fukuda,et al.  Mortality associated with influenza and respiratory syncytial virus in the United States. , 2003, JAMA.

[35]  C. Fraser,et al.  Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong , 2003, The Lancet.

[36]  I. Longini,et al.  The critical vaccination fraction for heterogeneous epidemic models. , 2003, Mathematical biosciences.

[37]  Susan Mallett,et al.  A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. , 2003, The Journal of antimicrobial chemotherapy.

[38]  W. Casscells,et al.  Influenza as a Bioweapon , 2003 .